Clinical Trials Browser

Active not recruiting × Adenocarcinoma Of Esophagus × Oxaliplatin × Clear all

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04248452 2026-03-02

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Phase 3 Active not recruiting

314 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT05152147 2026-02-27

HERIZON-GEA-01

Phase 3 Active not recruiting

920 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT05329766 2026-02-27

EDGE-Gastric

Phase 2 Active not recruiting

332 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05945823 2025-12-29

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

53 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT04210115 2024-11-15

KEYNOTE 975

Phase 3 Active not recruiting

703 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT02509286 2024-05-08

ESOPEC

Phase 3 Active not recruiting

438 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

Clinical Trials

STAR-221

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

HERIZON-GEA-01

EDGE-Gastric

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

KEYNOTE 975

ESOPEC